Fig. 1

Boanmycin inhibits cell proliferation and induces cell apoptosis in multiple myeloma cells. (A) RPMI 8226, U266B1, and MM.1 S cells were exposed to varying concentrations and durations of boanmycin, after which the relative cell viability was assessed using the CCK8 reagent. (B) Cell morphology was evaluated through Wright-Giemsa staining with and without boanmycin treatment. (C) RPMI 8226 and U266B1 cells were treated with 0, 0.4 and 0.8 µg/mL of boanmycin for approximately 15 days, after which the colonies were photographed, and (D) the number of colonies was counted. (E) Apoptosis analysis was performed via flow cytometry using Annexin V/PI staining, and (F) the proportion of total apoptotic cells was determined. (G) Western blot analysis of PARP, cleaved PARP, cleaved caspase 3, and cleaved caspase 7 in MM cells treated with boanmycin for 48 h. α-Tubulin served as a control. (mean ± SD, *p < 0.05, **p < 0.01 and ***p < 0.001)